Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
1. A therapeutic preparation comprising etanercept,
the therapeutic preparation being (i) shaped as a solid tissue penetrating member having a pointed tip, (ii) configured to be contained in a swallowable capsule, and (iii) configured to be inserted into an intestinal wall after oral ingestion of the capsule,
wherein upon insertion, the preparation releases etanercept into the blood stream from the intestinal wall, a t max for the etanercept released from the therapeutic preparation being less than about 80% of a t max for an extravascularly injected dose of etanercept.
2. The therapeutic preparation of claim 1 , wherein the extravascular injection is a subcutaneous injection or an intramuscular injection.
3. The therapeutic preparation of claim 1 , wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member.
4. The therapeutic preparation of claim 1 , wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release etanercept into the blood stream.
5. The therapeutic preparation of claim 1 , wherein a weight percent of etanercept in the tissue penetrating member comprises between about 8% to about 12%.
6. The therapeutic preparation of claim 1 , wherein a dose of etanercept in the preparation is in a range from about 1 mg to about 5 mg.
7. The therapeutic preparation of claim 1 , wherein the preparation is configured to produce a long-term release of etanercept to produce a selectable t 1/2 .
8. A therapeutic preparation comprising etanercept,
the therapeutic preparation being (i) shaped as a solid tissue penetrating member having a pointed tip, (ii) configured to be contained in a swallowable capsule, and (iii) configured to be inserted into an intestinal wall after oral ingestion of the capsule,
wherein upon insertion, the preparation releases etanercept into the blood stream from the intestinal wall to achieve a C max in a shorter time period than a time period to achieve a C max for an extravascularly injected dose of etanercept.
9. The therapeutic preparation of claim 8 , wherein the extravascular injection is a subcutaneous injection or an intramuscular injection.
10. The therapeutic preparation of claim 8 , wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member.
11. The therapeutic preparation of claim 8 , wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release etanercept into the blood stream.
12. The therapeutic preparation of claim 8 , wherein a weight percent of etanercept in the tissue penetrating member comprises between about 8% to about 12%.
13. The therapeutic preparation of claim 8 , wherein a dose of etanercept in the preparation is in a range from about 1 mg to about 5 mg.
14. The therapeutic preparation of claim 8 , wherein the preparation is configured to produce a long-term release of etanercept to produce a selectable t 1/2 .
15. A therapeutic preparation comprising etanercept,
the therapeutic preparation being shaped as a solid tissue penetrating member having a pointed tip and configured to be contained in a swallowable capsule and inserted into an intestinal wall after oral ingestion of the capsule;
wherein a weight percent of etanercept in the tissue penetrating member is between about 8% to about 12%.
16. The therapeutic preparation of claim 15 , wherein upon insertion, the preparation releases etanercept into the blood stream from the intestinal wall, a t max for the etanercept released from therapeutic preparation being less than about 80% of a t max for an extravascularly injected dose of etanercept.
17. The therapeutic preparation of claim 15 , wherein upon insertion, the preparation releases etanercept into the blood stream from the intestinal wall to achieve a C max in a shorter time period than a time period to achieve a C max for an extravascularly injected dose of etanercept.
18. The therapeutic preparation of claim 15 , wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member.
19. The therapeutic preparation of claim 15 , wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release etanercept into the blood stream.
20. The therapeutic preparation of claim 15 , wherein a dose of etanercept in the preparation is in a range from about 1 mg to about 5 mg.
21. The therapeutic preparation of claim 15 , wherein the preparation is configured to produce a long-term release of etanercept to produce a selectable t 1/2 .
22. The therapeutic preparation of claim 15 , wherein the tissue penetrating member has a weight in a range of about 10 mg to about 15 mg.